Peanut NE01 vaccine - BlueWillow Biologics
Alternative Names: NanoVax-Peanut vaccine; Peanut-NE01 vaccine; Peanut-NE01 vaccine - BlueWillow BiologicsLatest Information Update: 28 Nov 2023
At a glance
- Originator BlueWillow Biologics
- Class Food allergy immunotherapies; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Peanut hypersensitivity
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Peanut-hypersensitivity(Prevention) in USA (Intranasal)
- 01 Oct 2019 Bluewillow Biologics receives SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) for Peanut NE01 vaccine development in Peanut hypersensitivity
- 01 Oct 2019 Preclinical trials in Peanut hypersensitivity (Prevention) in USA (Intranasal) before October 2019